Adam Leo Stone
CIK 1727440 · Chief Executive Officer · last filed 2026-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.42M
Companies
9
Total Filings
21
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FRNM | 2,352,500 | — | — | $0 | 1 | 2026-07-22 | |
| IMTX | Director | — | $8.66 | — | $0 | 1 | 2026-06-18 |
| SLDB | Director | — | $8.06 | — | $0 | 10 | 2026-06-11 |
| ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Chief Executive Officer | 0 | $6.64 | $0 | $0 | 2 | 2024-07-31 |
| PCSC | Chief Executive Officer | 286,250 | $11.95 | $3.42M | $0 | 1 | 2024-06-13 |
| LianBio (LIAN) Delisted | Interim CEO | 36,300 | $0.32 | $11.6K | $0 | 3 | 2024-02-20 |
| ARYA Sciences Acquisition Corp V (ARYE) Delisted | Chief Executive Officer | 499,000 | $10.36 | $5.17M | $0 | 1 | 2021-07-15 |
| Nautilus Biotechnology, Inc. (ARYA) Delisted | Chief Executive Officer | 499,000 | $11.16 | $5.57M | $0 | 1 | 2020-08-11 |
| Cerevel Therapeutics Holdings, Inc. (CATB) Delisted | Chief Executive Officer | 499,000 | $8.54 | $4.26M | $0 | 1 | 2020-06-09 |
Recent Filings · Page 2 of 3
21 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-15 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2022-06-27 | LianBio (LIAN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2021-07-15 | ARYA Sciences Acquisition Corp V (ARYE) Delisted | Grant (A) | +499,000 | $4.99M | EDGAR |
| 2021-03-02 | ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Grant (A) | +499,000 | $4.99M | EDGAR |
| 2020-08-11 | Nautilus Biotechnology, Inc. (ARYA) Delisted | Other (J) | +499,000 | $4.99M | EDGAR |
| 2020-06-18 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2020-06-09 | Cerevel Therapeutics Holdings, Inc. (CATB) Delisted | Other (J) | +499,000 | $4.99M | EDGAR |
| 2019-06-17 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2018-12-17 | SLDB | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.